Wolverine Trading’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-12,500
| Closed | -$1.88M | – | 5695 |
|
|
2025
Q2 | $1.88M | Buy |
12,500
+8,100
| +184% | +$1.08M | ﹤0.01% | 1756 |
|
|
2025
Q1 | $684K | Buy |
4,400
+900
| +26% | +$151K | ﹤0.01% | 2615 |
|
|
2024
Q4 | $642K | Sell |
3,500
-2,400
| -41% | -$462K | ﹤0.01% | 3111 |
|
|
2024
Q3 | $1.17M | Sell |
5,900
-800
| -12% | -$166K | ﹤0.01% | 2195 |
|
|
2024
Q2 | $1.38M | Buy |
6,700
+4,800
| +253% | +$1.09M | ﹤0.01% | 1890 |
|
|
2024
Q1 | $515K | Sell |
1,900
-1,000
| -34% | -$239K | ﹤0.01% | 2816 |
|
|
2023
Q4 | $686K | Sell |
2,900
-2,000
| -41% | -$393K | ﹤0.01% | 2635 |
|
|
2023
Q3 | $960K | Buy |
4,900
+800
| +20% | +$164K | ﹤0.01% | 2139 |
|
|
2023
Q2 | $858K | Buy |
+4,100
| New | +$816K | ﹤0.01% | 2128 |
|
|
2023
Q1 | – | Sell |
-4,700
| Closed | -$1.02M | – | 4336 |
|
|
2022
Q4 | $1.02M | Buy |
4,700
+2,100
| +81% | +$459K | ﹤0.01% | 1828 |
|
|
2022
Q3 | $494K | Sell |
2,600
-2,700
| -51% | -$583K | ﹤0.01% | 2614 |
|
|
2022
Q2 | $1.16M | Sell |
5,300
-2,400
| -31% | -$586K | ﹤0.01% | 1793 |
|
|
2022
Q1 | $2.23M | Sell |
7,700
-10,800
| -58% | -$3.33M | ﹤0.01% | 1666 |
|
|
2021
Q4 | $6.95M | Sell |
18,500
-400
| -2% | -$155K | 0.01% | 933 |
|
|
2021
Q3 | $8M | Buy |
18,900
+13,100
| +226% | +$5.44M | 0.01% | 958 |
|
|
2021
Q2 | $2.16M | Buy |
5,800
+2,500
| +76% | +$835K | ﹤0.01% | 1908 |
|
|
2021
Q1 | $950K | Sell |
3,300
-3,200
| -49% | -$890K | ﹤0.01% | 2821 |
|
|
2020
Q4 | $1.62M | Sell |
6,500
-700
| -10% | -$167K | ﹤0.01% | 1906 |
|
|
2020
Q3 | $1.6M | Sell |
7,200
-17,600
| -71% | -$3.65M | ﹤0.01% | 1656 |
|
|
2020
Q2 | $4.19M | Buy |
24,800
+17,900
| +259% | +$2.86M | 0.01% | 914 |
|
|
2020
Q1 | $897K | Buy |
+6,900
| New | +$1.03M | ﹤0.01% | 2035 |
|
|
2019
Q4 | – | Sell |
-8,400
| Closed | -$1.11M | – | 4724 |
|
|
2019
Q3 | $1.11M | Buy |
+8,400
| New | +$1.13M | ﹤0.01% | 1879 |
|
|
2018
Q3 | – | Sell |
-5,400
| Closed | -$576K | – | 5029 |
|
|
2018
Q2 | $576K | Hold |
5,400
| – | – | ﹤0.01% | 2893 |
|
|
2018
Q1 | $576K | Sell |
5,400
-6,600
| -55% | -$711K | ﹤0.01% | 2893 |
|
|
2017
Q4 | $1.31M | Buy |
+12,000
| New | +$1.31M | ﹤0.01% | 1927 |
|
|
2016
Q4 | – | Sell |
-4,500
| Closed | -$371K | – | 4518 |
|
|
2016
Q3 | $371K | Sell |
4,500
-2,700
| -38% | -$226K | ﹤0.01% | 2945 |
|
|
2016
Q2 | $580K | Buy |
+7,200
| New | +$593K | ﹤0.01% | 2087 |
|
Other funds holding CRL
AI
Wolverine Trading's CRL Position: Q3 2025 in Review
Wolverine Trading sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 3,628 shares — an estimated $544K sold.
Wolverine Trading first reported a position in CRL in Q1 2018 and held it in 16 quarters. The position peaked at $2.26M in Q2 2021. 554 funds tracked by Wall St. Rank hold CRL as of Q3 2025.
- Wolverine Trading reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
- Wolverine Trading sold 3,628 Charles River Laboratories shares in Q3 2025, an estimated $544K.
- Wolverine Trading first reported a position in Charles River Laboratories in Q1 2018 and held it in 16 quarters.
- Wolverine Trading's Charles River Laboratories position peaked at $2.26M in Q2 2021.
- 554 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.